 |
|
|
|
|
| |
|
Constellation Pharmaceuticals Selected by
AlwaysOn as an OnDC Top 100 Winner
-Recognized for
Leading Innovation in Biotechnology-
Cambridge, MA, October 8, 2009
– Constellation Pharmaceuticals, Inc., the leading
biopharmaceutical company focused on discovering and
developing new drugs targeting epigenetic regulation of
the human genome, today announced that it has been
chosen by AlwaysOn as one of the OnDC Top 100 Winners.
Inclusion in the OnDC 100 signifies major developments
in the creation of new business opportunities that
contribute to the renewed and continued prosperity of
our country. Constellation Pharmaceuticals was specially
selected by the AlwaysOn editorial team and industry
experts spanning the globe based on a set of five
criteria: innovation, market potential,
commercialization, stakeholder value, and media buzz.
“It’s no secret that technology and innovation are vital
to bringing our country out of economic recession and
transforming important sectors like energy and
healthcare,” said Tony Perkins, founder and CEO of
AlwaysOn. “We congratulate the OnDC 100 for their
success in introducing new tools, services, and systems
to address the nation’s top priorities.”
“Being selected as one of the top OnDC winners is an
honor that highlights Constellation’s potential to make
a significant impact for patients through epigenetics,
the next biological breakthrough offering promise for
targeting disease above and beyond the genome,” said
Mark A. Goldsmith, M.D., Ph.D., Chief Executive Officer
of Constellation Pharmaceuticals. “We have built a
world-class team as evidenced by the recent hiring of Ed
Harlow, a leading cancer biologist, as our Chief
Scientific Officer. With our strong scientific team and
innovative product engine we should continue making
great progress toward discovering a new class of drugs
that ameliorate human disease by modulating the
epigenome.”
The OnDC 100 winners were selected from among hundreds
of other technology companies nominated by investors,
bankers, journalists and industry insiders. The AlwaysOn
editorial team conducted a rigorous three-month
selection process to finalize the 2009 list.
Constellation Pharmaceuticals is the leading
biopharmaceutical company dedicated to the discovery and
development of novel drugs targeting selective
regulators of epigenetic function. The company raised a
$32 million Series A financing and is currently building
a preclinical pipeline of epigenetic drugs.
Epigenetics is an exciting new field of biology that
involves chemical modifications of both DNA and of its
packaging proteins (“chromatin”), which are collectively
called the ‘epigenome.’ The genome, or DNA, is the
“blueprint” for the human body, consisting of thousands
of genes, which are the fundamental units of information
necessary for normal cell growth and development. In
contrast, the epigenome plays a critical role in
regulating the expression of genes, that is, switching
genes on or off – or in the case of disease, for
switching genes on or off incorrectly. This new field of
Epigenetic science provides the opportunity to create a
broad new class of human therapeutics targeting
selective regulators of epigenetic function.
Constellation Pharmaceuticals and the OnDC Top 100
Companies will be honored at AlwaysOn’s OnDC event on
October 19th-21st at the Four Seasons Hotel in
Washington DC. This two-and-a-half-day executive event
features CEO presentations and high-level debates on
sectors most impacted by the federal government
including greentech, on-demand computing and IT
security, education, and the life sciences.
A full list of all the OnDC Top 100 Winners can be found
on the AlwaysOn Web site at
http://alwayson.goingon.com/permalink/post/33638
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is the leading
biopharmaceutical company dedicated to the development
of novel therapeutics in the emerging field of
Epigenetics, a new field of science that focuses on
selective regulators of gene function and expression.
Constellation’s initial focus is in oncology, and the
Company’s platform will also be applicable to other
therapeutic areas including autoimmune, inflammatory and
neurological diseases. The Company’s academic founders
represent the core thought leaders in epigenetics
responsible for key advances, insights and discoveries
in the field. Constellation Pharmaceuticals is located
in Cambridge, Massachusetts. For more information,
please visit the company's website at
www.constellationpharma.com.
About AlwaysOn
AlwaysOn ignited the open-media revolution in early 2003
by being the first media brand to launch a global blog
network. In 2004, AlwaysOn continued to lead the media
industry in innovation by introducing a social network
where members can connect and engage. AlwaysOn is also
revolutionizing the media business by applying its
open-media principles to its executive event series
(Summit at Stanford, OnMedia, OnHollywood, OnDC,
GoingGreen East and West, Venture Summit East and West)
and quarterly print “blogozine” by empowering its
members to post and share their ideas and meet each
other online. As our loyal readers know, AlwaysOn is
committed to the free-market, merit-driven approach to
reporting and event programming. No other media brand
has dared to create such open interaction with its
readers and event participants.
Contact
Adriana Jenkins
For Constellation Pharmaceuticals
617 744 1713
adrianajenkins@gmail.com
|
|
|
|
